Sharmin Ghaznavi, MD, PhD, is the Associate Director and the Scientific Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics (CNP) at Massachusetts General Hospital. She is leading the Center’s first studies on the effects of psilocybin on rumination and other cognitive processes in treatment resistant depression. Dr. Ghaznavi also serves as a psychiatrist at the MGH Dauten Family Center for Bipolar Treatment Innovation and is an instructor in Psychiatry at Harvard Medical School. Dr. Ghaznavi received her undergraduate degrees in biology, brain and cognitive sciences, and philosophy from the Massachusetts Institute of Technology. She obtained her medical degree, masters degree in philosophy, and PhD in neuroscience from Yale University and completed a residency in adult psychiatry at the Mass General/McLean Psychiatry Residency Program. She has been the recipient of the Dupont-Warren and Livingston psychiatric research fellowships from Harvard Medical School and a 2012 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation.